Keynote Session 2: Clinical Trial Keynote

12:40-1:30 PM, November 22, 2026; Room 10A-D

Speaker
  • Marc BuyseIDDI and One2treat; Hasselt University, Belgium
Moderator

Clinical Trials: Focusing on Things that Matter

Speaker: Marc Buyse, IDDI and One2treat, Louvain-la-Neuve, Belgium; I-BioStat, Hasselt University, Belgium
Biography

Marc Buyse

Marc Buyse holds degrees in engineering, management, statistics and a ScD in biostatistics from the Harvard School of Public Health. He worked at the European Organization for Research and Treatment of Cancer (EORTC) in Brussels and at the Dana Farber Cancer Institute in Boston, MA, prior to founding IDDI, CluePoints and One2Treat, companies offering services and software for clinical research. He is Associate Professor of biostatistics at Hasselt University in Belgium. He has co-authored several books and ~ 500 peer-reviewed papers on statistical methods for surrogate endpoint validation, detection of errors in clinical data, analysis of multiple prioritized outcomes for patient-centric medicine. He proposed the Net Treatment Benefit as a measure of treatment effect in randomized clinical trials (see Marc E Buyse - Publications List).

Abstract

The last decade has seen an extraordinary proliferation of novel biostatistical methods for clinical trials, and the coming wave of AI-based approaches is likely to accelerate this trend. Against this backdrop, it seems especially important to focus on “things that matter”: methods and ideas that are not merely elegant, innovative, or complex, but that have the potential to transform clinical research in the 21st century and beyond.

I will structure this talk around five considerations at the heart of every clinical trial: (1) experimental design, (2) analytical methods, (3) patients, (4) treatments, and (5) outcomes. Statisticians have made major contributions to the first two, but have arguably been less influential in shaping the last three. I will argue that the most consequential advances in clinical research may come from developments that receive little attention in the statistical literature: embedding clinical trials in routine patient care, focusing on outcomes that truly matter to patients, and systematically sharing and reusing data from completed trials.

These developments are methodologically less glamorous than many of the innovations currently attracting our attention, but their impact could be far greater. As statisticians, we should help shape them, even when doing so takes us beyond the traditional boundaries of our profession.


Moderator: Susan Halabi

Duke University Medical Center
Biography

Susan Halabi

Susan Halabi, PhD, is the James B. Duke Distinguished Professor of Biostatistics and Bioinformatics and Co-Chief of the Division of Biostatistics, Department of Biostatistics and Bioinformatics at Duke University Medical Center. For more than 25 years, she has been a leader in the design and analysis of oncology clinical trials, developing innovative statistical methods for clinical studies, biomarkers, and high-dimensional data. Her research has made significant contributions to prognostic modeling in prostate cancer and the identification and validation of surrogate endpoints for overall survival. Dr. Halabi has authored more than 330 peer-reviewed publications and co-edited two foundational books, Oncology Clinical Trials (2nd Edition, Demos, 2018) and Textbook of Clinical Trials in Oncology (CRC Press, 2019). A past president of the Society for Clinical Trials, she is a Fellow of the Society for Clinical Trials, the American Statistical Association, and the American Society of Clinical Oncology, and has received numerous prestigious awards for her contributions to biostatistics and oncology research.


Back to agenda · All Keynote Sessions